New Imaging Biomarkers Predictive of MA Progression

Study acronym: MR7T-PRADA
StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 1 entry Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 5 of 5 entries
    • Site details revised
  2. Primary completion date: Oct 2, 2026 to Oct 2, 2027
    • Study completion date: Jan 15, 2027 to Jan 15, 2028
    • Eligibility criteria shortened, about 2 words
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Primary completion date: Dec 15, 2026 to Oct 2, 2026
    • Start date changed from estimate of Dec 15, 2023 to Oct 2, 2023
    v3
  4. Start date: Jul 15, 2023 to Dec 15, 2023
    • Primary completion date: Jul 15, 2026 to Dec 15, 2026
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The pathophysiology of AD is complex. In addition to amyloid plaques and neurofibrillary degeneration, there is a metabolic alteration of the energy pathways, oxidative phosphorylation and glycolysis, which are involved in brain function. Several authors have shown a series of early metabolic dysregulations via an increase in phosphorylation at the origin of neuronal death. Ultra-high field imaging (7T MRI) may allow, with its better spatial resolution and advanced imaging techniques, to shed light on the mechanisms of progression of Alzheimer's disease. A Magnetic Resonance Spectroscopy (MRS) examination can be coupled to brain MRI without additional risk for the patient. Multinuclear 1H-31P metabolic imaging is a promising tool that can provide information on the metabolic evolutionary profile of AD. Thus, we propose a longitudinal study in patients with early-stage AD on 7T MRI-MRS.
Trial Details
NCT Number NCT05939362
Lead Sponsor Poitiers University Hospital
Conditions
(from sponsor)		 Alzheimer Disease, Magnetic Resonance Spectroscopy, Ultra High Field 7T, Progression of Disease, MR Biomarkers
Related terms Alzheimer Disease
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov